MXPA05003340A - Metodo para tratamiento de pacientes con perdida masiva de sangre. - Google Patents
Metodo para tratamiento de pacientes con perdida masiva de sangre.Info
- Publication number
- MXPA05003340A MXPA05003340A MXPA05003340A MXPA05003340A MXPA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A
- Authority
- MX
- Mexico
- Prior art keywords
- hemoglobin
- solution
- polymerized
- molecular weight
- blood
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 210000004369 blood Anatomy 0.000 title claims abstract description 67
- 239000008280 blood Substances 0.000 title claims abstract description 67
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 272
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 272
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 210000003743 erythrocyte Anatomy 0.000 claims description 75
- 229920000642 polymer Polymers 0.000 claims description 20
- 230000036772 blood pressure Effects 0.000 claims description 12
- 231100000419 toxicity Toxicity 0.000 claims description 12
- 230000001988 toxicity Effects 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 8
- 206010047139 Vasoconstriction Diseases 0.000 claims description 7
- 239000000356 contaminant Substances 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 7
- 230000025033 vasoconstriction Effects 0.000 claims description 7
- 206010021138 Hypovolaemic shock Diseases 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 206010040560 shock Diseases 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 239000000243 solution Substances 0.000 description 124
- 108010034539 PolyHeme Proteins 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000001802 infusion Methods 0.000 description 16
- 208000032843 Hemorrhage Diseases 0.000 description 14
- 208000014674 injury Diseases 0.000 description 13
- 230000008733 trauma Effects 0.000 description 13
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006392 deoxygenation reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010002255 deoxyhemoglobin Proteins 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PREOBXYMXLETCA-UHFFFAOYSA-N 2-[4-(2-carboxyphenoxy)-4-oxobutanoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCC(=O)OC1=CC=CC=C1C(O)=O PREOBXYMXLETCA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000219873 Vicia Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- -1 iraidoesters Chemical compound 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002103 osmometry Methods 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41593502P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031377 WO2004037279A1 (en) | 2002-10-03 | 2003-10-03 | Method for treating patients with massive blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05003340A true MXPA05003340A (es) | 2005-07-05 |
Family
ID=32176456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05003340A MXPA05003340A (es) | 2002-10-03 | 2003-10-03 | Metodo para tratamiento de pacientes con perdida masiva de sangre. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7291592B2 (enExample) |
| EP (1) | EP1553968A4 (enExample) |
| JP (1) | JP2006502231A (enExample) |
| CN (1) | CN1703235A (enExample) |
| AU (1) | AU2003272827B2 (enExample) |
| CA (1) | CA2499459A1 (enExample) |
| MX (1) | MXPA05003340A (enExample) |
| NO (1) | NO20051390L (enExample) |
| RU (1) | RU2325924C2 (enExample) |
| WO (1) | WO2004037279A1 (enExample) |
| ZA (1) | ZA200502307B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049707A1 (en) * | 2003-08-29 | 2005-03-03 | Ferree Bret A. | Cemented artificial disc replacements |
| US7747315B2 (en) * | 2002-01-15 | 2010-06-29 | Board Of Regents, The University Of Texas System | Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| EP1978802A2 (en) * | 2006-01-24 | 2008-10-15 | Northfield Laboratories, Inc. | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
| WO2008009635A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| RU2361608C1 (ru) * | 2008-03-18 | 2009-07-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" | Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты) |
| RU2452519C1 (ru) * | 2011-03-25 | 2012-06-10 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации |
| EP3655019A4 (en) | 2017-07-18 | 2021-04-21 | Virtech Bio, Inc. | BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464814A (en) | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US4826811A (en) | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5194590A (en) * | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5854209A (en) | 1995-03-23 | 1998-12-29 | Biopure Corporation | Method for oxygenating tissue having reduced red blood cell flow |
| US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
| US5955581A (en) | 1986-11-10 | 1999-09-21 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| AU705225B2 (en) * | 1995-03-23 | 1999-05-20 | Biopure Corporation | Stable polymerized hemoglobin blood substitute |
| US20020065211A1 (en) | 1995-03-23 | 2002-05-30 | Biopure Corporation | Increasing function of organs having reduced red blood cell flow |
| US5895810A (en) | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
| US6150507A (en) | 1995-03-23 | 2000-11-21 | Biopure Corporation | Method for producing a purified hemoglobin product |
| US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| US5691452A (en) | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US6271351B1 (en) | 1995-03-23 | 2001-08-07 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US5691453A (en) | 1995-06-07 | 1997-11-25 | Biopure Corporation | Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC |
| SK134398A3 (en) * | 1996-03-28 | 2001-01-18 | Northfield Lab | Aqueous solution of the pyridoxylated polymerized hemoglobin and method for preparing the same |
| US5890852A (en) * | 1998-03-17 | 1999-04-06 | Emerson Electric Company | Thread cutting die and method of manufacturing same |
-
2003
- 2003-10-03 AU AU2003272827A patent/AU2003272827B2/en not_active Expired - Fee Related
- 2003-10-03 RU RU2005113240/14A patent/RU2325924C2/ru not_active IP Right Cessation
- 2003-10-03 CN CNA2003801009126A patent/CN1703235A/zh active Pending
- 2003-10-03 CA CA002499459A patent/CA2499459A1/en not_active Abandoned
- 2003-10-03 EP EP03755029A patent/EP1553968A4/en not_active Withdrawn
- 2003-10-03 JP JP2004546786A patent/JP2006502231A/ja active Pending
- 2003-10-03 US US10/678,927 patent/US7291592B2/en not_active Expired - Fee Related
- 2003-10-03 MX MXPA05003340A patent/MXPA05003340A/es active IP Right Grant
- 2003-10-03 WO PCT/US2003/031377 patent/WO2004037279A1/en not_active Ceased
-
2005
- 2005-03-16 NO NO20051390A patent/NO20051390L/no not_active Application Discontinuation
- 2005-03-18 ZA ZA2005/02307A patent/ZA200502307B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003272827B2 (en) | 2009-03-19 |
| NO20051390L (no) | 2005-05-30 |
| CA2499459A1 (en) | 2004-05-06 |
| US7291592B2 (en) | 2007-11-06 |
| AU2003272827A1 (en) | 2004-05-13 |
| RU2005113240A (ru) | 2005-12-10 |
| RU2325924C2 (ru) | 2008-06-10 |
| WO2004037279A1 (en) | 2004-05-06 |
| US20040067876A1 (en) | 2004-04-08 |
| CN1703235A (zh) | 2005-11-30 |
| JP2006502231A (ja) | 2006-01-19 |
| EP1553968A4 (en) | 2009-06-24 |
| EP1553968A1 (en) | 2005-07-20 |
| ZA200502307B (en) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vogel et al. | Coronary constrictor effect of stroma-free hemoglobin solutions | |
| JP2554396B2 (ja) | 生物学的液体における病理学的疎水性相互作用を処置する方法および組成物 | |
| Johnson et al. | Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function | |
| Brzica et al. | Autologous blood transfusion | |
| EA030017B1 (ru) | Композиция для наружной обработки ран, способ ее получения, применение переносчика кислорода для наружной обработки ран и способ очистки переносчика кислорода | |
| Castro et al. | Improvement of sickle cell anemia by iron‐limited erythropoiesis | |
| AU2003272827B2 (en) | Method for treating patients with massive blood loss | |
| Keipert et al. | Pyridoxylated polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats | |
| IE61008B1 (en) | Composition for increasing the hematocrit of a normal mammal | |
| Henry et al. | The effect of experimental hemorrhagic shock on pulmonary alveolar surfactant | |
| Ichikawa et al. | Storage-related changes in autologous whole blood and irradiated allogeneic red blood cells and their ex vivo effects on deformability, indices, and density of circulating erythrocytes in patients undergoing cardiac surgery with cardiopulmonary bypass | |
| Brooks | Noncardiogenic pulmonary edema immediately following rapid protamine administration | |
| Przybelski et al. | A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock | |
| Gould et al. | The development of polymerized pyridoxylated hemoglobin solution as a red cell substitute | |
| Inada | Blood coagulation and autologous blood transfusion in cardiac surgery | |
| COOKE et al. | Cryoprecipitate concentrates of factor VIII for surgery in hemophiliacs | |
| Shiono et al. | Application of cryoprecipitate as a hematostatic glue | |
| Chmura et al. | Perioperative use of recombinant activated factor VII in liver transplantation | |
| Jovanovic et al. | Redo cardiac surgery in a Jehovah’s Witness, the importance of a multidisciplinary approach to blood conservation | |
| HK1084875A (en) | Method for treating patients with massive blood loss | |
| Tasaki et al. | Pharmacological approaches to reduce perioperative transfusion requirements in the aged | |
| Ala | Transfusion of Red Cells | |
| Pulliam | Use of blood and its components | |
| Gresens et al. | Other reactions and alloimmunization | |
| Spahn et al. | Augmented Acute Normovolemic Hemodilution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |